Company intelligence / Profile preview

Centella Therapeutics

Palo Alto, California, United States

Ownership: Private
Development stage: Other

Overview

CEN-209, a hypoxia-targeted prodrug designed to enhance radiotherapy and chemotherapy in hypoxic solid tumors, entered Cancer Research UK's CDP for pre-clinical development and Phase 1 trials in 2011. Centella had an option to buy back data post-Phase 1.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

CEN-209

Unknown

Partnerships

Cancer Research UKAuckland UniServices Ltd

Beyond the preview

Go deeper on Centella Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Centella Therapeutics.

Explore the full profile